Laboratorios [ROVI] vs Grifols, S.A [GRF] Detailed Stock Comparison
Laboratorios
BME
Loading...
Grifols, S.A
BME
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Laboratorios wins in 10 metrics, Grifols, S.A wins in 9 metrics, with 0 ties. Laboratorios appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Laboratorios | Grifols, S.A | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 20.56 | 29.19 | Laboratorios |
| Price-to-Book Ratio | 4.83 | 1.69 | Grifols, S.A |
| Debt-to-Equity Ratio | 22.50 | 126.87 | Laboratorios |
| PEG Ratio | 19.65 | 21.77 | Laboratorios |
| EV/EBITDA | 14.45 | 11.64 | Grifols, S.A |
| Profit Margin (TTM) | 17.66% | 4.00% | Laboratorios |
| Operating Margin (TTM) | 17.14% | 18.48% | Grifols, S.A |
| EBITDA Margin (TTM) | 17.14% | 18.48% | Grifols, S.A |
| Return on Equity | 25.01% | 4.99% | Laboratorios |
| Return on Assets (TTM) | 12.50% | 4.43% | Laboratorios |
| Free Cash Flow (TTM) | $76.06M | $530.80M | Grifols, S.A |
| Dividend Yield | 1.69% | N/A | N/A |
| 1-Year Return | -29.88% | 47.66% | Grifols, S.A |
| Price-to-Sales Ratio (TTM) | 3.64 | 1.05 | Grifols, S.A |
| Enterprise Value | $2.81B | $20.19B | Grifols, S.A |
| EV/Revenue Ratio | 3.75 | 2.71 | Grifols, S.A |
| Gross Profit Margin (TTM) | 65.93% | 39.33% | Laboratorios |
| Revenue per Share (TTM) | $15 | $11 | Laboratorios |
| Earnings per Share (Diluted) | $2.59 | $0.44 | Laboratorios |
| Beta (Stock Volatility) | 0.44 | 0.97 | Laboratorios |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Laboratorios vs Grifols, S.A Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Laboratorios | 1.22% | 1.13% | -2.45% | 1.99% | -2.71% | -16.02% |
| Grifols, S.A | 0.86% | 0.15% | 19.91% | 58.70% | 53.07% | 36.89% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Laboratorios | -29.88% | 4.78% | 92.65% | 323.23% | 1,127.17% | 458.73% |
| Grifols, S.A | 47.66% | -5.89% | -47.14% | -34.50% | 191.01% | 398.08% |
Performance & Financial Health Analysis: Laboratorios vs Grifols, S.A
| Metric | ROVI | GRF |
|---|---|---|
| Market Information | ||
| Market Cap | €2.72B | €7.81B |
| Market Cap Category | Large cap | Large cap |
| 10 Day Avg. Volume | 125,358 | 2,306,289 |
| 90 Day Avg. Volume | 122,417 | 2,044,540 |
| Last Close | €53.75 | €12.95 |
| 52 Week Range | €45.52 - €82.45 | €7.32 - €13.70 |
| % from 52W High | -34.81% | -5.44% |
| All-Time High | €94.80 (May 27, 2024) | €34.31 (Feb 17, 2020) |
| % from All-Time High | -43.30% | -62.26% |
| Growth Metrics | ||
| Quarterly Revenue Growth | -0.10% | 0.04% |
| Quarterly Earnings Growth | -0.26% | 6.89% |
| Financial Health | ||
| Profit Margin (TTM) | 0.18% | 0.04% |
| Operating Margin (TTM) | 0.17% | 0.18% |
| Return on Equity (TTM) | 0.25% | 0.05% |
| Debt to Equity (MRQ) | 22.50 | 126.87 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | €11.02 | €7.60 |
| Cash per Share (MRQ) | €0.93 | €0.86 |
| Operating Cash Flow (TTM) | €136.55M | €1.10B |
| Levered Free Cash Flow (TTM) | €7.13M | €718.49M |
| Dividends | ||
| Last 12-Month Dividend Yield | 1.69% | N/A |
| Last 12-Month Dividend | €0.94 | €0.00 |
Valuation & Enterprise Metrics Analysis: Laboratorios vs Grifols, S.A
| Metric | ROVI | GRF |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 20.56 | 29.19 |
| Forward P/E | 19.65 | 21.77 |
| PEG Ratio | 19.65 | 21.77 |
| Price to Sales (TTM) | 3.64 | 1.05 |
| Price to Book (MRQ) | 4.83 | 1.69 |
| Market Capitalization | ||
| Market Capitalization | €2.72B | €7.81B |
| Enterprise Value | €2.81B | €20.19B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 3.75 | 2.71 |
| Enterprise to EBITDA | 14.45 | 11.64 |
| Risk & Other Metrics | ||
| Beta | 0.44 | 0.97 |
| Book Value per Share (MRQ) | €11.02 | €7.60 |
Financial Statements Comparison: Laboratorios vs Grifols, S.A
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | ROVI | GRF |
|---|---|---|
| Revenue/Sales | €154.89M | €1.89B |
| Cost of Goods Sold | €64.49M | €1.15B |
| Gross Profit | €90.40M | €743.80M |
| Research & Development | N/A | €96.19M |
| Operating Income (EBIT) | €23.10M | €349.54M |
| EBITDA | €30.92M | €355.88M |
| Pre-Tax Income | €22.85M | €190.51M |
| Income Tax | €4.77M | €52.13M |
| Net Income (Profit) | €18.08M | €138.38M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | ROVI | GRF |
|---|---|---|
| Cash & Equivalents | €29.31M | €558.69M |
| Total Current Assets | €467.86M | €5.25B |
| Total Current Liabilities | €126.28M | €1.99B |
| Long-Term Debt | €85.27M | €8.43B |
| Total Shareholders Equity | €599.47M | €7.60B |
| Retained Earnings | €503.43M | €176.79M |
| Property, Plant & Equipment | N/A | €6.57B |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | ROVI | GRF |
|---|---|---|
| Operating Cash Flow | €54.81M | €1.22B |
| Capital Expenditures | €-8.06M | N/A |
| Free Cash Flow | €10.57M | €371.87M |
| Debt Repayment | €-6.22M | N/A |
| Common Stock Repurchase | €-14.69M | N/A |
Short Interest & Institutional Ownership Analysis
| Metric | ROVI | GRF |
|---|---|---|
| Shares Short | N/A | N/A |
| Short Ratio | N/A | N/A |
| Short % of Float | N/A | N/A |
| Average Daily Volume (10 Day) | 125,358 | 2,306,289 |
| Average Daily Volume (90 Day) | 122,417 | 2,044,540 |
| Shares Outstanding | 51.15M | 680.41M |
| Float Shares | 18.75M | 561.12M |
| % Held by Insiders | 0.63% | 0.31% |
| % Held by Institutions | 0.17% | 0.31% |
Dividend Analysis & Yield Comparison: Laboratorios vs Grifols, S.A
| Metric | ROVI | GRF |
|---|---|---|
| Last 12-Month Dividend | €0.94 | €0.00 |
| Last 12-Month Dividend Yield | 1.69% | N/A |
| 3-Year Avg Annual Dividend | €1.11 | €0.00 |
| 3-Year Avg Dividend Yield | 2.08% | N/A |
| 3-Year Total Dividends | €3.33 | €0.00 |
| Ex-Dividend Date | Jul 14, 2025 | N/A |